Enrique Grande, One Oncology Madrid Program Director at Quironsalud, shared on X:
“FDA approves belzutifan + lenvatinib for advanced ccRCC after PD-1/PD-L1 inhibitor therapy.
Based on LITESPARK-011: median PFS 14.6 vs 10.6 months (HR 0.74) vs cabozantinib. OS not significantly different at final analysis.”
You can also read:
Kidney Cancer in Numbers: Global Burden, Regional Differences and the Road to 2050
